2023. Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s136. DOI:https://doi.org/10.25251/skin.7.supp.136.